Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit
Kaleido Biosciences (Nasdaq: KLDO) announced that CEO Dan Menichella will participate in an analyst-led fireside chat at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The event emphasizes Kaleido's innovative, chemistry-driven approach to targeting the microbiome to treat diseases. The webcast will be available at 8 am EDT on Kaleido’s website, with an archived replay accessible for 90 days post-event. Kaleido focuses on developing Microbiome Metabolic Therapies (MMT) aimed at enhancing gut health and addressing unmet medical needs.
- None.
- None.
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit.
The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 90 days following the event.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com
Investors
Mike Biega
Solebury Trout
617-221-9660
mbiega@soleburytrout.com
Media
Amy Bonanno
Solebury Trout
914-450-0349
abonanno@soleburytrout.com
SOURCE: Kaleido Biosciences
FAQ
What event is Kaleido Biosciences participating in on April 22, 2021?
Who will represent Kaleido Biosciences at the Jefferies Summit?
When will the fireside chat webcast be available?
How long will the archived replay of the fireside chat be available?
What is the focus of Kaleido Biosciences' approach to healthcare?
